Bionano Genomics (NasdaqCM:BNGO) Q4 2025 Earnings call March 23, 2026 04:30 PM ET Company ParticipantsErik Holmlin - President and CEOMark Adamchak - VP of AccountingWebb Campbell - VPConference Call ParticipantsYi Chen - Managing Director and Senior AnalystOperatorGood day, and welcome to the Bionano Q4 and full year 2025 earnings conference call. Today's conference is being recorded. At this time, I would like to turn the conference over to Webb Campbell from Gilmartin Group. Please go ahead.Webb Campbell ...

Bionano Genomics (NasdaqCM:BNGO) Q4 2025 Earnings call March 23, 2026 04:30 PM ET Speaker2Good day, and welcome to the Bionano fourth quarter and full year 2025 earnings conference call. Today's conference is being recorded. At this time, I would like to turn the conference over to Webb Campbell from Gilmartin Group. Please go ahead.Speaker3Thank you, Carmen, and good afternoon, everyone. Welcome to Bionano's fourth quarter and full year 2025 financial results conference call. On the call today is Dr. Erik ...

Talphera (NasdaqGM:TLPH) Q4 2025 Earnings call March 23, 2026 11:00 AM ET Company ParticipantsJames Molloy - Managing Director, Equity ResearchJoao Teixeira - Associate Professor in Division of NephrologyShakil Aslam - Chief Medical OfficerSharon McMahon - Associate Professor of MedicineVincent Angotti - CEOConference Call ParticipantsEd Arce - Managing Director, Senior Research AnalystNazibur Rahman - VP and Biopharmaceuticals Equity Research AnalystYuan Zhi - Senior Equity Research AnalystModeratorGood mo ...

Talphera (NasdaqGM:TLPH) Q4 2025 Earnings call March 23, 2026 11:00 AM ET Company ParticipantsJoao Teixeira - Associate Professor in Division of NephrologyShakil Aslam - Chief Medical OfficerSharon McMahon - Associate Professor of MedicineVincent Angotti - CEOConference Call ParticipantsEd Arce - Managing Director and Senior Research AnalystJim Molloy - Managing Director and Biotechnology and Specialty Pharmaceuticals Equity Research AnalystNazibur Rahman - VP and Biopharmaceuticals Equity Research AnalystY ...

Talphera (NasdaqGM:TLPH) Q4 2025 Earnings call March 23, 2026 11:00 AM ET Speaker4Good morning, everyone, and welcome to the Talphera Virtual Analyst and Investor Event. At this time, all attendees are in a listen-only mode. A question and answer session will follow the formal presentations. As a reminder, this call is being recorded, and a replay will be made available on the Talphera website following the conclusion of the event. I'd now like to turn the call over to Vince Angotti, Chief Executive Officer ...

Lithium Argentina (NYSE:LAAC) Q4 2025 Earnings call March 23, 2026 10:00 AM ET Company ParticipantsAnthony Taglieri - Equity Research AssociateCorinne Blanchard - Director of Equity ResearchKelly O'Brien - VP of Investor Relations and ESGSam Pigott - President and CEOConference Call ParticipantsBen Isaacson - Managing Director and Equity Research AnalystJoel Jackson - Managing Director and Equity Research AnalystMohamed Sidibé - Equity Research AnalystOperatorHello everyone, and welcome to Lithium Argentina ...

Caledonia Mining (NYSEAM:CMCL) Q4 2025 Earnings call March 23, 2026 10:00 AM ET Speaker6Welcome to the Caledonia Mining quarterly and full-year results 2025 presentation for analysts and investors. I would now like to hand you over to Mark Learmonth, who is the CEO. Mark, over to you.Speaker3Good afternoon and welcome to this management conference call. If we could move to the first slide of the presentation, please. Just go to the disclaimer. That's the standard disclaimer. If we could move on to the next ...

Lithium Argentina (NYSE:LAAC) Q4 2025 Earnings call March 23, 2026 10:00 AM ET Speaker6Hello everyone, and welcome to Lithium Argentina fourth quarter and full year 2025 earnings conference call. Please note that this call is being recorded. After the prepared remarks, there will be a question and answer session. If you'd like to ask a question during that time, please press star followed by one on your telephone keypad. Thank you. I'd now like to hand the call over to Kelly O'Brien, Investor Relations. Ple ...

BioLineRx (NasdaqCM:BLRX) Q4 2025 Earnings call March 23, 2026 08:30 AM ET Company ParticipantsElla Sorani - Chief Development OfficerIrina Koffler - Investor Relations OfficerMali Zeevi - CFOPhilip Serlin - CEOConference Call ParticipantsJoe Pantginis - Managing Director and Equity Research AnalystJohn Vandermosten - Senior AnalystJustin Walsh - AnalystOperatorLadies and gentlemen, thank you for standing by. Welcome to the BioLineRx fourth quarter and full year 2025 financial results conference call. All p ...

Financial Data and Key Metrics Changes - Revenues for the year ended December 31, 2025, were $1.2 million, a significant decrease from $28.9 million in 2024, primarily reflecting royalties from APHEXDA sales [19] - Research and development expenses decreased to $8.1 million in 2025 from $9.2 million in 2024, mainly due to lower expenses related to motixafortide and a decrease in headcount [20] - General and administrative expenses fell to $3.1 million in 2025 from $6.3 million in 2024, attributed to a reversal of a provision for doubtful accounts and reduced payroll expenses [21] - Net loss for 2025 was $2 million, down from $9.2 million in 2024, indicating improved financial performance [21] - Cash and equivalents at year-end 2025 were approximately $21 million, sufficient to fund operations into the first half of 2027 [12][21] Business Line Data and Key Metrics Changes - APHEXDA generated sales of $6.5 million in 2025, resulting in $1.2 million of royalty revenue to the company [13] - The company continues to support the development of motixafortide in pancreatic cancer, with enrollment in the Chemo4METPANC trial accelerating [11] Market Data and Key Metrics Changes - The total addressable market for glioblastoma is estimated to exceed $3.7 billion in the U.S. and Europe, with an expected annual incidence of approximately 18,500 patients in the U.S. and 13,500 in the EU by 2030 [8] Company Strategy and Development Direction - The company is focused on advancing GLIX1, a novel treatment for glioblastoma, with plans to initiate a phase I/II-A trial by the end of the month [4][5] - GLIX1 has received orphan drug designation from both the FDA and the European Medicines Agency, which will expedite its review process [5] - The company aims to expand GLIX1's development into additional cancer indications once safety and dosing are established [10] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the potential of GLIX1 to address significant unmet needs in glioblastoma treatment, highlighting the lack of advancements in the standard of care since 2005 [7] - The company is well-positioned to drive innovation in challenging cancer types and is excited about future developments [57] Other Important Information - A legal dispute with Biokine Therapeutics was resolved in favor of the company, removing a financial overhang and allowing a focus on GLIX1 development [17] Q&A Session Summary Question: Potential for interim data in GBM study - Management clarified that the phase I study is primarily focused on safety and recommended dose, with efficacy as a secondary endpoint [28][29] Question: Enthusiasm from principal investigators for GLIX1 trial - There is significant enthusiasm from investigators regarding GLIX1's novel mechanism of action and preclinical results, with eagerness to initiate the study [39] Question: Update on Gloria's phase III bridging trial - Management reported that Gloria has started the bridging study for stem cell mobilization, with patient recruitment underway, but no interim readouts expected due to the study's blinded nature [44][46] Question: Eligibility of patients for investigational therapies in GLIX1 study - Patients enrolled in the GLIX1 study are recurrent or progressed GBM patients, typically having exhausted standard care options [47] Question: Ayrmid's guidance on expected sales - Management indicated that Ayrmid has not provided long-term sales guidance, as they are still ramping up operations [53]